Should marijuana access be expanded? On April 23, 2026, the Trump administration … – Facebook
✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchMedical MarijuanaMental Health Clinical Summary The Trump administration’s April 2026 policy…
The Biggest Things About Schedule III You Haven’t Thought Of | Cannabis Business Times
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustry Clinical Summary # Clinical Summary The potential rescheduling of cannabis from Schedule I to…
Federal marijuana reclassification could reshape medical research and cannabis industry
✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustryAging Clinical Summary The potential federal reclassification of marijuana from Schedule I to a…
Justice Department, DEA ordered to reclassify state-licensed medical cannabis as less … – Maui Now
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchSafety Clinical Summary A federal court has ordered the Department of Justice and DEA to reclassify…
Cannabis Use and Falls in Elderly: New Trauma Center Data – CED Clinic
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. AgingSafetyResearchNeurology Why This Matters # Why This Matters ClinicallyClinicians treating elderly patients need…
Elevated Cannabis Use Tied to Higher Anxiety and Symptom Burden in Opioid Use Disorder Patients
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. AnxietyMental HealthResearchSafety Why This Matters Clinicians treating patients with opioid use disorder on…
What Federal Cannabis Rescheduling Means for Care
Cannabis Schedule III rescheduling marks a major shift in how cannabis is classified and understood at the federal level. This change begins to align policy with clinical reality, affecting research, documentation, and patient access. Cannabis Schedule…
Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy.
A comprehensive review explores cannabidiol brain tumor antiepileptic mechanisms and suggests potential antitumor activity in CNS cancers. The analysis identifies multiple pathways through which CBD and other antiepileptic drugs might combat brain tumors…
Opioid Use Disorder Among Cervical Fusion Inpatients: Trends, Complications, and Resource Use in a Retrospective National Inpatient Sample Analysis, 2016-2022.
A large retrospective study reveals that opioid use disorder affects 3.4% of cervical fusion surgery patients, with these individuals experiencing significantly longer hospital stays and higher complication rates. This population-level data provides…
The cannabidiol (CBD): Tetrahydrocanabinol (THC) concentration ratio is critical for neuroprotection and recovery following traumatic brain injury.
Preclinical research demonstrates that specific CBD THC ratio neuroprotection mechanisms outperform CBD isolate in traumatic brain injury models. This study supports the entourage effect hypothesis while highlighting the need for human clinical trials to…